EKSISTENSI “THE TRIPS SAFEGUARDS” DI DALAM PERJANJIAN TRIPS: DALAM PERSPEKTIF KESEHATAN MASYARAKAT

https://doi.org/10.22146/jmh.16297

Tomi Suryo Utomo(1*)

(1) 
(*) Corresponding Author

Abstract


Developing countries believe that the TRIPS Agreement gives more benefits to pharmaceutical companies of developed countries and prevents access to cheaper and affordable drugs. A reduction of drug prices has occurred when developing countries applied safeguards, such as parallel imports and compulsory license. The effort to enact safeguard legislation has resulted in US legal action, such as the dispute between the US government and the Brazilian government when Brazil considered the adoption of compulsory license. Another example was a dispute between big pharmaceutical companies and the South African government in its plans for adoption of parallel imports and compulsory license. These disputes demonstrate that the TRIPS safeguard articles are weak and meaningless because the interpretation of those articles has favored the developed countries’ perspectives.


Full Text:

PDF



DOI: https://doi.org/10.22146/jmh.16297

Article Metrics

Abstract views : 1691 | views : 2341

Refbacks

  • There are currently no refbacks.


Copyright (c) 2008 Tomi Suryo Utomo

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Mimbar Hukum Indexed by:

DOAJ (Directory of Open Access Journal) Bielefeld Academic Search Engine (BASE) COREWorldCatLIVIVOCopac JISTHarvard LibraryElectronic Journals LibraryColumbia University LibrariesLeiden University LibrariesUniversity of Saskatchewan-CanadaGent University LibraryWestern Theological SeminaryUniversity of OxfordThe University of SheffieldThe University of Manchester Toronto Public LibraryEbsco  

Member of :

Crossref


MIMBAR HUKUM ISSN: 0852-100X(print), ISSN: 2443-0994(online)